F Dx Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History

F Dx Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$31.09 - $37.88 $6,559 - $7,992	-211 Reduced 2.91%	7,040 $251,000
Q3 2022 Nov 10, 2022	SELL	$28.79 - $35.41 $11,170 - $13,739	-388 Reduced 5.08%	7,251 $245,000
Q2 2022 Aug 03, 2022	SELL	$25.33 - $34.25 $3,216 - $4,349	-127 Reduced 1.64%	7,639 $221,000
Q1 2022 May 03, 2022	BUY	$28.51 - $32.9 $20,897 - $24,115	733 Added 10.42%	7,766 $251,000
Q4 2021 Feb 01, 2022	BUY	$26.37 - $34.22 $185,460 - $240,669	7,033 New	7,033 $205,000
Q1 2018 May 02, 2018	SELL	$37.15 - $46.9 $205,959 - $260,013	-5,544 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$36.4 - $42.6 $1,929 - $2,257	53 Added 0.97%	5,544 $221,000
Q3 2017 Nov 03, 2017	SELL	$36.75 - $49.65 $20,139 - $27,208	-548 Reduced 9.07%	5,491 $220,000
Q2 2017 Aug 11, 2017	BUY	N/A	6,039	6,039 $260,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.